The RNA-dependent RNA polymerase of influenza virus transcribes messenger RNA through a unique cap-scavenging mechanism. The polymerase binds to the cap structure at the 5' ends of host mRNAs, which are then cleaved and used as primers for viral mRNA synthesis. In an effort to discover antiviral compounds against this target, an in-vitro transcription assay was utilized to screen a proprietary chemical collection. Results of this screening effort identified an N-hydroxamic acid structure as an inhibitor of the capped RNA-dependent transcriptase activity. SUbsequent sub-structure searching and screening based upon this pharmacophore identified two related N-hydroxy-imide compounds as specific inhibitors. These compounds were found to inhibit the cap-scavenging mechanism through inhibition of . the endonuclease function of the polymerase.
Introduction
Influenza A and B viruses are a major cause of epidemic and pandemic upper respiratory infections worldwide and are responsible for a high percentage of mortality among the immune compromised and the elderly (Couch, 1993) .
The effectiveness of current vaccines is limited by the rapid antigenic drift and shift of the major virus surface antigens (Webster and Bean, 1978) and despite aggressive vaccination programmes, significant numbers still contract the disease. The currently approved drugs are amantadine and the related rimantadine, which target the influenza M2 protein (Hay, 1992) . These drugs are limited by the rapid emergence of drug-resistant virus during therapeutic treatment and the lack of activity against influenza B virus (Betts, 1991 (Betts, , 1992 Hayden et al., 1991; Hayden and Couch, 1992; Hayden and Hay, 1992) . In addition, amantadine has been implicated in causing sideeffects in the central nervous system (Betts, 1992; Stoof et aI., 1992) .
Influenza virus encodes its own RNA-dependent RNA polymerase, a heterotrimeric protein complex essential for viral genome expression and replication (Ishihama and Nagata, 1988) . The polymerase is encoded by the three largest segments of the viral genome, encompassing c.a. 50% of the coding capacity of the virus. Polymerase sequences are relatively well conserved among the different influenza subtypes, and even between influenza A and B viruses (Scholtissek, 1978; Lamb and Choppin, 1983; Yamashita et al., 1989; Gorman et al., 1990) , suggesting that the polymerase represents a good strain-and subtype-independent specific drug target.
The first step of influenza viral replication is the transcription of its negative (-) sense viral RNA (vRNA) to (+) sense messenger RNA (mRNA). However, the influenza virus has no 5' mRNA capping enzyme of its own. In order to ensure efficient translation of its own messages by cellular machinery, the influenza virus utilizes a cap-scavenging mechanism, whereby the 5' cap-containing portion of host mRNAs are used as viral mRNA primers (Krug et al., 1989) . The viral polymerase binds to the 5' cap structure of nascent cellular mRNAs in the nuclei of infected cells, cleaves them 9-15 nucleotides downstream, then utilizes these capped RNA fragments as primers for transcription (Krug, 1981; Plotch et al., 1981; Braam et el., 1983) . Therefore, the influenza polymerase possesses several unique activities, such as capped RNA binding and endonucleolytic cleavage functions, as well as an RNA-directed RNA transcription activity. An in-vitro transcription assay (Bishop et el., 1971; Krug et al., 1980; Kawakami et al., 1985) was utilized to screen chemical collections for the presence of inhibitory compounds. This assay utilizes a capped mRNA as a substrate for cleavage and elongation, thereby evaluating all three steps of primary transcription. Certain compounds, possessing either N-hydroxamic acid or N-hydroxy-imide residues, were identified as inhibitors in this assay. Further mechanistic studies identified the endonuclease activity of the influenza polymerase as the specific step of enzyme inhibition. A high throughput in-vitro transcription assay was used to screen the Bristol-Myers Squibb chemical collection for specific inhibitors of the influenza transcriptase. This screen uses purified viral RNP cores as the source of enzyme and a capped mRNA (either cap [ + 1] modified AIMV RNA 4 or rabbit globin mRNA) as primer. From this collection, a lead compound, BMY-26270 ( Fig. 1) , was identified as a selective inhibitor of purified influenza A RNA-dependent RNA polymerase, with an IC so c.a. 40 IlM (Fig. 1) . In order to assess activity against influenza subtype B virus, detergent solubilized (0.25%[v/v] Triton-N101) influenza B was compared to identically prepared influenza A in the presence of increasing concentrations of BMY-26270. Figure 2 shows that BMY-26270 inhibited the in-vitro capped RNA-dependent transcription of the influenza B viral polymerase with nearly identical potency Inhibition of incorporation of radioactivity was assayed as described and data corrected as in Fig. 1 to the A subtype influenza virus. However, when counterassayed against the RNA-dependent RNA polymerase of vesicular stomatitis virus (VSV), BMY-26270 proved to be inactive (Fig. 2. ). Vesicular stomatitis virus and influenza virus are both negative stranded RNA viruses that utilize a virally encoded polymerase to transcribe their genomic vRNA into mRNA after cellular entry. However, the VSV polymerase initiates transcription of its RNP de novo, without the need for capped primers or an associated endonuclease. The VSV has RNP-associated guanylyl-and methyl-transferase activities allowing for post-transcriptional guanosine 5'-triphosphate (GTP) capping and methylation, respectively, of nascent mRNA transcripts (Banerjee, 1987) . Additional experiments designed to examine specificity of inhibition by BMY-26270 were conducted using viral cores and ApG as primer. At sufficiently high concentrations adenylyl (3'-75') guanosine (ApG) will prime viral RNA synthesis directly off the viral template, thereby bypassing the endonuclease function (Krug et al., 1989) . The BMY-26270 preferentially inhibited cap-dependent transcription over ApG primed transcription. In addition, BMY-26270 is relatively inactive against bacteriophage T7 polymerase, a DNA-dependent RNA polymerase (Table 1) .
Results

Selective inhibition of the influenza RNA-dependent RNA polymerase by BMY-26270
BMY-26270 [IlM]
Fig. 1. Chemical structure of BMY-26270 and inhibition profile of BMY-26270 in a capped RNA primed polymerase assay using influenza viral cores. Inhibition of incorporation of radioactivity was assayed as described. Data are corrected for background incorporation and expressed as a percentage of uninhibited control transcription. BMY -26270 concentration expressed in 11M.
Inhibition of the endonuc/eolytic cleavage of capped RNA by BMY-26270
The selectivity of BMY-26270 for influenza virus polymerase over VSV polymerase suggests that this compound acts on a mechanism unique to influenza virus. 
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than their prototypes 1 and 4, respectively. However, influenza polymerase inhibitory activlty is less sensitive to the nature of the template if the hydroxamic acid is incorporated into a cyclic ring system, as in BMS-183355 (13) and BMS-183021 (14) , both of which demonstrate inhibitory potency comparable to that of BMY-26270 (1).
Inhibition of the influenza RNA-dependent RNA polymerase by N-hydroxy-imides occurs through inhibition of the endonucleolytic cleavage of capped RNA
Structure-activity relationship studies of the hydroxamic acid BMY -26270 identified two related N-hydroxy-imides, BMS-183355 (13) and BMS-183021 (14) ( Fig. 4 ) as viral polymerase inhibitors, with ICsos of c.a. 50 IlM. These compounds were further analysed in endonuclease and
"Average of three determinations.
One possible unique target is the cap-scavenging activity associated with the influenza virus polymerase. Previously, we had developed and used an in-vitro endonuclease assay to examine the cleavage requirements of the viral transcriptase . This assay uses a 67 nucleotide synthetic cap [ + 1] containing RNA radiolabelled in its cap structure. In this assay, the 67nt substrate RNA is incubated with polymerase and activity is monitored by the generation of a single radiolabelled 11 nucleotide cleavage product. Figure 3a shows that BMY-26270 inhibits the generation of the 5'-radiolabelled capped 11-nt cleavage product in a concentration-dependent manner. The cleavage product was quantified in a Betascope 603 analyser (Betagen, Mountain View, CA) and the results are shown graphically in Fig. 3b . The calculated IC so for inhibition of cleavage is 40 IlM, which is similar to that determined for overall capped RNA-dependent transcription. In an effort to illuminate aspects of the structure-activity relationships (SAR) associated with BMY-26270 ( Fig. 1) , a series of structurally related compounds were selected for evaluation from the Bristol-Myers Squibb compound collection. The results of this survey, which are summarized in Fig. 4 , provide a rudimentary understanding of the nature and disposition of the important pharmacophoric elements. It is apparent from the data presented in the table that the two relatively acidic functional groups present in BMY-26270 (1), the phenolic hydroxyl and the hydroxamic acid moiety, are essential components of the polymerase-inhibiting pharmacophore. Modification or deletion of either of these elements in the context of the equi-active pyridine homologue (4) leads to a series of uniformly inactive compounds (5-8). Moreover, their topological relationship is optimal as configured in BMY-26270 (1) since the isomeric compound 3 is a significantly weaker polymerase inhibitor. The template on which these functional elements are presented to the enzyme is also of paramount importance, highlighting the subtlety of the underlying SAR. Naphthalene analogue 2 and the monocyclic heterocycles 9-12 are over 100-fold weaker cap-RNA binding assays (Cianci at a/., 1995) . Fig. 5a shows that both compounds inhibit the generation of the 5'-capped 11-nt cleavage product in a concentrationdependent manner with ICsos of 30 I-lM and 40 I-lM for BMS-183355 and BMS-183021, respectively. At 50 I-lM, BMS-183355, BMS-183021 and BMY-26270 also inhibited the endonuclease reaction preferentially over capped RNA binding when compared with the cap analogue m7GpppGm, as shown in Fig. 5b . BMS-183355 was further examined for effect solely against elongation activity. Viral cores and mRNA were incubated in the presence of Mg++ but the absence of nucleoside 5'-triphosphates (NTPs) and compounds. This allows for cleavage of the mRNA to form a primer, but elongation does not occur. Then BMS-183355 was added followed by the NTPs. Upon incubation, transcription ensued and analysis of product assays for inhibition of elongation only. In this experiment, BMS-183355 does not exhibit significant inhibitory activity at concentrations as high as 400 I-lM (data not shown), suggesting that this compound does not significantly inhibit the elongation activity of the polymerase.
Discussion
The influenza virus polymerase is an important target for antiviral intervention, as it carries out a number of virusspecific activities. Besides functioning as an RNA-dependent RNA polymerase, this heterotrimer also exhibits the unique and necessary functions of capped RNA binding to host mRNAs and endonucleolytically cleaving them into short primers. Utilizing an in-vitro assay, we have identified several related compounds that inhibit capped RNA transcription by viral polymerase cores. The first compound identified, BMY-26270, is a selective in-vitro inhibitor of influenza polymerase catalyzed cap-dependent transcription. Moreover, BMY-26270 inhibits the polymerases of both influenza A and B viruses, which are the two most clinically relevant viral subtypes. The BMY-26270 does not inhibit the viral RNA-dependent RNA ..
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polymerase of vesicular stomatitis virus or the DNAdependent RNA polymerase of bacteriophage T7.
Evaluation of several analogues of BMY-26270 (1) identified the hydroxamic acid and phenol moieties as structural elements essential for effective influenza polymerase inhibitory activity and also defined their optimal regiochemical relationship. Further refinement of the topology of the pharmacophore is apparent in the structurally related N- hydroxy-imides, BMS-183355 (13) and BMS-183021 (14) , where the relatively acidic amine NH presumably functions as an isostere of the phenolic hydrogen. While compound 4 was reported as the synthetic precursor to a compound found to be inactive as an agonist at the strychnine-sensitive glycine receptor (Drummond et al., 1989) , this is the first report of influenza virus inhibitory properties for this class of compound. Interestingly, the cyclic hydroxamic acids 13 and 14 are potent inhibitors of glycine binding to the allosteric modulator site of the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor (Romine et al., 1994) . It should be noted though, that when tested in vivo for the ability of these compounds to protect cells from influenza infection, the compounds themselves proved toxic, with CCsos in the low I-lM range. Therefore, we could not evaluate their antiviral potential in vivo.
N-hydroxamic acid is a known metal chelating ligand group found in many naturally occurring microbial compounds (Raymond et aI., 1982) . However, the possibility that the inhibition arises from chelation of the Mg++ ion by these compounds is unlikely because the Mg++ concentration used in these assays is 5 mM and much higher than the micromolar inhibitory concentrations obtained for these compounds. Furthermore, N-hydroxamic acids are more selective for trivalent metal ions than divalent metal ions (Martell and Smith, 1982) . In fact, if a ferric complex of BMY-26270 is pre-formed in situ, all inhibitory potency is lost, indicating that the functional groups must be in an uncomplexed form for activity (data not shown).
Secondary assays were used to help identify the specific step inhibited by these three compounds.
Biochemical assays indicate that the endonucleolytic cleavage of capped RNAs is inhibited by BMS-183355, BMS-183021 and BMY-26270. This step is believed to be carried out by the PB2 subunit of the viral polymerase (Plotch et aI., 1981; Ulmanen et al., 1981; Braam et al., 1983; Shi et al., 1995) . These compounds could be working through direct interaction with the PB2 subunit, or they could also function indirectly through interaction with other subunits of the polymerase. In order to have functional endonuclease activity, all three subunits must be complexed Shi et al., 1995) .
The similar ICsos of BMS-183355, BMS-183021 and BMY-26270 in overall transcription and in direct measurements of capped RNA-dependent endonucleolytic cleavage are consistent with the rate-determining step in overall primary transcription being cleavage to form primers. They inhibit endonuclease activity preferentially over capped RNA binding activity (3-4-fold). This is in contrast with cap analogue m7GpppGm and short capped oligonucleotides, which inhibit cap binding and endonuclease at equivalent levels (Fig. 5 ). Previously, we had shown that capped oligonucleotides too short to be used for transcription but capable of being recognized by the poly- merase are highly potent inhibitors of transcription . This implies that the primer binding site is multi-functional, comprising a discrete cap recognition domain along with a separate RNA binding 'groove'. These hydroxamic and hydroxy-imide compounds do show partial inhibition of dinucleotide (ApG) primed transcription, but at concentrations 5-6-fold greater than those required for inhibition of capped RNA primed transcription. This would be consistent with inhibition of the endonuclease activity resulting from the compound binding some distance from the cap binding site yet close to the cleavage site and/or the ApG binding site. This is supported by the delayed addition assay using BMS-183355. In this experiment, mRNA is allowed to bind to polymerase and be cleaved to primer size, but elongation does not result due to lack of NTPs. Addition of BMS-183355 and NTPs then permits analysis of the compound solely on the elongation activity, as the primer is already bound to polymerase. The BMS-183355 did not significantly inhibit transcription at concentrations up to 400 flM, suggesting that the inhibition seen with this compound when ApG is used to prime RNA synthesis is not due to the inhibition of elongation. These results would imply that BMS-183355, BMS-183021 and BMY-26270 do not prevent the RNA interaction with the proposed groove, but functions close to the endonuclease or ApG binding site.
Recently, two other endonuclease inhibitors have been reported. One class of inhibitors are 4-substituted 2,4 dioxobutanoic acid derivatives (Tomassini et al., 1994; Hastings et al., 1996) . The other is a cyclic Nhydroxy-imide, termed flutimide, which was isolated from a natural product (Hensens, 1995; Singh, 1995; Tomassini et al., 1996) . There is clear structural homology between flutimide and the active polymerase inhibitors identified in this study, particularly the cyclic hydroxamic acid moiety found in BMS-183355 and BMS-183021: However, flutimide lacks the weakly acidic NH found in the two N-hydroxy-imides reported here, suggesting that this functional element may be of lesser importance in cyclic hydroxamic acid influenza polymerase inhibitors.
Materials and Experimental Procedures
Growth of influenza virus and purification of viral cores
Influenza A1PRl8 virus (H1 N1) or B/Lee/40 virus were grown in the allantoic sacs of 1O-day old embryonated eggs and isolated by differential centrifugation (Barrett and Inglis, 1985) . Viral cores were prepared from 2-3 mg of whole virus by disruption with 1.5% Triton-N101 and 10 mg mL-1 of lysolecithin in 100 mM Tris-HCI (pH 8.0), 100 mM KCI, 5 mM MgCI 2, 5% glycerol (w/v), and 1.5 mM dithiothreitol .
The ribonucleoprotein (RNP) cores (0.5 fl9) were purified on glycerol gradients as described by Rochavansky (1976) .
Transcriptase assays
In-vitro cap-dependent transcriptions were conducted as described by Plotch et al. (1981) . Reactions were run in 50 mM TAPS KOW1, pH 8.3,100 mM KCI, 5 mM MgCI 2, 2 mM orr, with 10 mg mL-1 E. colitRNA 100 mM ATP, 20 mM CTP, 20 mM GTP, 10 mM UTP (2 Ci/mmol [a-35SjUTP) at 31°C with either 0.5 fl9 viral cores or 2 fl9 Triton N-101 (0.25%) treated virus (Cianci et al., 1995) . After incubating for 60 min trichloroacetic acid (5%) was added and precipitablecounts were monitoredby an LKB RackBeta liquid scintillation counter. Enzymatically methylated cap-1 alfalfa mosaic virus (AIMV) RNA at 7.5 ng mL-1 (Barbosa and Moss, 1978; Koper-Zwarthoff, 1980) or globin mRNA at 15 ng mL-1 (GIBCO/BRL, Gaithersburg, MD) served as capped RNA primers. For the delayed drug addition experiment, endonuclease reactions (see below) were performed for 20 min at 31°C in the absence of NTPs to allow for cleavage of mRNA. Compound and NTPs are subsequently added and transcription allowed to proceed for 60 min and products assayed as above. Non-influenza DNA-dependent RNA polymerase (bacteriophage T7) transcription was incubated at 37"C for 35 min as described by the manufacturer (New England Biolabs, Waltham, MA) using a linearized plasmid DNA with a T7 promoter (3 fl9 mL-1 ) and T7 RNA polymerase (13 Units mL-1 ) , 40 mM Tris-HCI, pH 7.4,60 mM NaCI, 5 mM spermidine, 6 mM MgCI 2, 500 flM ATP, CTP, and GTP, 100 flM UTP (0.1 Ci/mmol [a-35SjUTP). Vesicular stomatitis virus (VSV) RNA-dependentRNA polymerase was purified and RNA transcriptions run as described by Banerjee et al. (1974) .
Non-cap-dependent (ApG) transcription was performed with 500 flM of ApG (Sigma Chemical Co., St Louis, MO), which was substituted for capped primers in standard transcription reactions. Compounds for testing were dissoved in DMSO and diluted into assay cocktail, achieving a final concentration of 2.5% DMSO.
Cap-dependent endonuclease cleavage and binding assays
Endonuclease reactions were accomplished as described by Chung et al. (1994) . Briefly, RNA transcripts (67-nt) were prepared by in-vitro run-off transcription from Smal digested pGEM@-7Zf(+) plasmid DNA (Promega Corp, Madison WI). Transcripts were extracted with phenol/chloroform, chromatographed through Quik-Spin@ G-25 columns (Boehringer Mannheim, Indianapolis, IN), and ethanol precipitated. The 5' triphosphorylated ends of the RNA transcriptswere convertedto 32P-radiolabelled cap-1 structures by concurrent capping and methylation reactions (25 flL) containing mRNA guanylyltransferase/(guan ine-7-)-methyltransferase/5 '-triphosphatase enzyme complex from vaccinia virus (GIBCO/BRL, Gaithersburg, MD) as described . For cleavage and binding assays, a typical 20 ul, reaction contained 10-30 nM (25-100 x 10 3 cpm) of capped pGEM@-7Zf(+) derived probe and 0.5 fl9 of viral cores. The reaction buffer also contained 50 mM Hepes, 100 mM NaCI, 2 mM OTT, 100 fl9 mL-1 yeast tRNA and 20 units of RNasin (Promega, Madison, WI). Endonuclease reactions also contained 5 mM MgCI 2. Reaction products were analysed by 7 M urea polyacrylamide gel electrophoresis. Capped RNA binding reactions were performed as described by Cianci et al. (1995) . Following incubation for 15 min at 31"C, T1 RNase was added to digest the RNA tail portion of the probe. Then 5 ILLof anti-PB2 peptide sera was added and incubation continued on ice for 15 min (Blok et al., 1996) . Twenty ILL of a suspension of Protein-G (Pharmacia) was added and the sample rocked for 20 min. After three cycles of washing with 0.05 M Tris pH 7.8,150 mM NaCI, 0.02% NPAO and once with PBS, the Protein-G was resuspended in 500 ILL of H 2 0 , combined with 4 mL of Opti-Fluor scintillation cocktail and assayed in an LKB Rack-Beta counter.
